Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design

Ahmed A Khattab, Stephan Windecker, Peter Jüni, David Hildick-Smith, Dariusz Dudek, Henning R Andersen, Reda Ibrahim, Gerhard Schuler, Antony S Walton, Andreas Wahl, Heinrich P Mattle, Bernhard Meier, Ahmed A Khattab, Stephan Windecker, Peter Jüni, David Hildick-Smith, Dariusz Dudek, Henning R Andersen, Reda Ibrahim, Gerhard Schuler, Antony S Walton, Andreas Wahl, Heinrich P Mattle, Bernhard Meier

Abstract

Background: Several studies have shown an association of cryptogenic stroke and embolism with patent foramen ovale (PFO), but the question how to prevent further events in such patients is unresolved. Options include antithrombotic treatment with warfarin or antiplatelet agents or surgical or endovascular closure of the PFO. The PC-Trial was set up to compare endovascular closure and best medical treatment for prevention of recurrent events.

Methods: The PC-Trial is a randomized clinical trial comparing the efficacy of percutaneous closure of the PFO using the Amplatzer PFO occluder with best medical treatment in patients with cryptogenic embolism, i.e. mostly cryptogenic stroke. Warfarin for 6 months followed by antiplatelet agents is recommended as medical treatment. Randomization is stratified according to patients age (<45 versus ≥45 years), presence of atrial septal aneurysm (ASA yes or no) and number of embolic events before randomization (one versus more than one event). Primary endpoints are death, nonfatal stroke and peripheral embolism.

Discussion: patients were randomized in 29 centers of Europe, Canada, and Australia. Randomization started February 2000. Enrollment of 414 patients was completed in February 2009. All patients will be followed-up longitudinally. Follow-up is maintained until the last enrolled patient is beyond 2.5 years of follow-up (expected in 2011).

Trial registration: ClinicalTrials.gov NCT00166257.

References

    1. Hart R, Miller V. Cerebral infarction in young adults: a practical approach. Stroke. 1983;14:110–114.
    1. Jones H, Caplan L, Come P. et al.Cerebral emboli of paradoxical origin. Ann Neurol. 1983;13:314–319. doi: 10.1002/ana.410130315.
    1. Job FP, Hanrath P. The diagnosis, clinical significance and therapy of patent foramen ovale. Dtsch Med Wochenschr. 1996;121:919–925. doi: 10.1055/s-2008-1043088.
    1. Falk V, Walther T, Krankenberg H, Mohr FW. Trapped thrombus in a patent foramen ovale. Thorac Cardiovasc Surg. 1997;45:90–92. doi: 10.1055/s-2007-1013695.
    1. Mirode A, Tribouilloy C, Adam MC, Poulain H, Lesbre JP. Echocardiographic diagnosis of a thrombus trapped in a patent foramen ovale. Apropos of a case. Arch Mal Coeur Vaiss. 1993;86:1065–1068.
    1. Caes FL, Van Belleghem YV, Missault LH, Coenye KE, Van Nooten GJ. Surgical treatment of impending paradoxical embolism through patent foramen ovale. Ann Thorac Surg. 1995;59:1559–1561. doi: 10.1016/0003-4975(94)00892-B.
    1. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148–1152. doi: 10.1056/NEJM198805053181802.
    1. Lechat P, Lascault G, Mas JL, Loron P, Klimczac K, Guggiari M, Drobinski G, Fraysse JB, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in young patients with ischemic cerebral complications. Arch Mal Coeur Vaiss. 1989;82:847–852.
    1. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, Glasgow GL. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11–112. doi: 10.1016/S0140-6736(88)92944-3.
    1. Hausmann D, Mugge A, Becht I, Daniel WG. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol. 1992;70:668–672. doi: 10.1016/0002-9149(92)90210-P.
    1. Mas JL. Patent foramen ovale, aneurysm of the interatrial septum and cerebral ischemic complication. Ann Cardiol Angeiol (Paris) 1996;45:531–537.
    1. Mattle HP, Meier B, Nedeltchev K. Prevention of stroke in patients with patent foramen ovale. Int J Stroke. 2009;5:92–102. doi: 10.1111/j.1747-4949.2010.00413.x.
    1. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J. 1995;130:1083–1088. doi: 10.1016/0002-8703(95)90212-0.
    1. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxical Embolism Study Group. Neurology. 1996;46:1301–1305.
    1. Messe SR, Silverman IE, Kizer JR. et al.Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;62:1042–50.
    1. Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86:1902–1908.
    1. Chatterjee T, Aeschbacher B, Meier B. Non-surgical closure of secundum atrial septal defect and patent foramen ovale. Schweiz Med Wochenschr. 1997;127:2054–2060.
    1. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139:753–760.
    1. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, Mattle HP, Meier B. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750–758. doi: 10.1016/j.jacc.2004.05.044.
    1. ACC/AHA cardiac catheterization ad hoc task force. ACC/AHA guidelines for cardiac catheterization and cardiac catheterization laboratories. J Am Coll Cardiol. 1991;18:1149–1182. doi: 10.1016/0735-1097(91)90533-F.
    1. Rao P, Sideris E, Hasudorf G, Rey C, Lloyd T. International experience with secundum atrial septal defect occlusion by the buttoned device. Am Heart J. 1994;128:1022–1035. doi: 10.1016/0002-8703(94)90602-5.
    1. Sideris E, Leung M, Han Yoon J, Chen C, Lochan R. Occlusion of large atrial septal defects with a centering buttoned device: early clinical experience. Am Heart J. 1996;131:356–359. doi: 10.1016/S0002-8703(96)90366-X.
    1. Das G, Voss G, Jarvis G, Wyche K, Gunther R, Wilson R. Experimental atrial septal defect closure with a new transcatheter self-centering device. Circulation. 1993;88:1754–1764.
    1. Arabia F, Rosado L, Llyod T, Sethi G. Mangement of complications of Sideris transcatheter device for atrial septal defect closure. J Thorac Cardiovasc Surg. 1993;106:886–888.
    1. Sievert H, Ensslen R, Spiess H, Scherer D, Merle H. Nicht-operativer Verschluss des Vorhofseptumdefektes bei Erwachsenen. Dtsch Med Wochenschr. 1994;119:1341–1345. doi: 10.1055/s-2008-1058843.
    1. Schräder R, Schneider M, Teupe C, Winkelmann B. Verschluss eines Vorhofseptumdefektes mittels Schirmprothese. Dtsch Med Wochenschr. 1995;120:321–324.
    1. Hirsh J. Oral anticoagulant drugs. New Engl J Med. 1991;324:1865–1874. doi: 10.1056/NEJM199106273242606.
    1. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation. 1994;89:1469–1481.
    1. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148–1152. doi: 10.1056/NEJM198805053181802.
    1. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, Glasgow GL. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11–12. doi: 10.1016/S0140-6736(88)92944-3.
    1. de Belder MA, Tourikis L, Leech G, Camm AJ. Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol. 1992;69:1316–1320. doi: 10.1016/0002-9149(92)91228-V.
    1. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461–465.
    1. Hausmann D, Mugge A, Becht I, Daniel WG. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol. 1992;70:668–672. doi: 10.1016/0002-9149(92)90210-P.
    1. Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, Chedru F, Guerin F, Bousser MG, de Recondo J. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993;24:1865–1873.
    1. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a metaanalysis of case-control studies. Neurology. 2000;55:1172–1179.
    1. Sacco RL, Adams R, Albers G. et al.Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577–617. doi: 10.1161/01.STR.0000199147.30016.74.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel